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The description of the disease sitosterolemia by Bhattacharyya and Connor initiated a fundamental rewrite of
how dietary sterols traffic and are eliminated by the body
(1). And while sitosterolemia, named after the most abundant xenosterol detected in the plasma of the two affected
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sisters, was described in 1974, the disease is ancient, with
mutant alleles that are several thousand years old (2). We
know that the genetic locus whose dysfunction leads to
sitosterolemia encodes two genes, ABCG5 and ABCG8, whose
proteins function as obligate heterodimers (3, 4). ABCG5
and ABCG8 (also known as sterolins) are expressed only in
hepatocytes, gallbladder epithelium, and enterocytes, and
are responsible for excretion of sterols, with xenosterols
preferred over cholesterol. Arguably, the naming of the
disease has led to a bias in appreciating the fact that sterolins keep a vast range of xenosterols, not just sitosterol,
from accumulating in the body (5). A better name should
be xenosterolemia to reflect appreciation of this biology.
Although the spectrum of xenosterols our diets contain
is extensive, we show a few sterol structures that highlight
the differences between cholesterol and these xenosterols (Fig. 1). In general, the major differences reside in
the R tail of the sterol structure, with change in shape
that will likely impact their organization in membranes
(6–8).
While the importance of cholesterol trafficking is wellrecognized for its roles in the pathogenesis of endothelial
dysfunction, foam-cell formation, and atherosclerosis,
ensuring that xenosterols are kept out and why [an evolutionary mechanism, conserved from fish to man (9)], has
garnered less attention. The loss of function in humans,
as well as in animal models, shows that accumulation of

Abbreviations: ASCVD, atherosclerotic CVD; FCA, fractional cholesterol absorption; FNSE, fractional neutral sterol excretion; FXR,
farnesoid X receptor; LXR, liver X receptor; PBC, primary biliary cirrhosis;
RCT, reverse cholesterol transport; TG, triglyceride; TICE, transintestinal
cholesterol excretion; WTD, Western-type diet.
This review is dedicated to the memory of Bill Connor; not only was
his impact in the field of cholesterol significant, but without his first
description of this disease with his colleague Dr. Bhattacharyya, we may
have waited a long time before stumbling upon these key proteins.
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Abstract The elucidation of the molecular basis of the rare
disease, sitosterolemia, has revolutionized our mechanistic
understanding of how dietary sterols are excreted and how
cholesterol is eliminated from the body. Two proteins,
ABCG5 and ABCG8, encoded by the sitosterolemia locus,
work as obligate dimers to pump sterols out of hepatocytes
and enterocytes. ABCG5/ABCG8 are key in regulating wholebody sterol trafficking, by eliminating sterols via the biliary
tree as well as the intestinal tract. Importantly, these transporters keep xenosterols from accumulating in the body.
The sitosterolemia locus has been genetically associated
with lipid levels and downstream atherosclerotic disease,
as well as formation of gallstones and the risk of gallbladder
cancer. While polymorphic variants raise or lower the risks
of these phenotypes, loss of function of this locus leads to
more dramatic phenotypes, such as premature atherosclerosis, platelet dysfunction, and thrombocytopenia, and, perhaps, increased endocrine disruption and liver dysfunction.
Whether small amounts of xenosterol exposure over a lifetime cause pathology in normal humans with polymorphic
variants at the sitosterolemia locus remains largely unexplored. The purpose of this review will be to summarize
the current state of knowledge, but also highlight key conceptual and mechanistic issues that remain to be explored.—
Patel, S. B., G. A. Graf, and R. E. Temel. ABCG5 and ABCG8:
more than a defense against xenosterols. J. Lipid Res. 2018.
59: 1103–1113.

Fig. 1. Sterol structures of cholesterol as well as some xenosterols. The structure of cholesterol in two views viewed “en face” and from a
side (top and bottom, respectively) is shown in the far right. The mesh indicates the overall surface-based shape of the sterol, based upon the
carbons and hydrogens, and the 3-hydroxyl oxygen is shown in red in all molecules at the bottom left of each molecule for orientation. The
“R” tail at the right end of each molecule shows the greatest difference between cholesterol and the xenosterols. Note in the bottom profile
that stigmasterol (yellow) looks very similar to cholesterol (magenta), but in the top row profile shows the bulkiness of its R tail compared with
cholesterol. Thus the packing of these sterols in a lipid bilayer will be affected by the differences in the R tail of each of these molecules.

in the bile leading to the formation of gallstones, prolonged inflammation, generation of genotoxic agents, and
then oncogenesis.
Studies of these genetic variants have been association
studies (30) and none have demonstrated a specific mechanistic pathway altered by these variants; we assume that
cholesterol pumping into the bile or intestine would be
altered. However, the liver has a predilection for excretion
of xenosterols into bile (31), and the hypothesis that one of
these dietary xenosterols is mechanistically involved has
not been explored.

GENETIC VARIATION AT THE SITOSTEROLEMIA
LOCUS AND CLINICAL IMPLICATIONS

CLINICAL MANIFESTATIONS

ABCG5 and ABCG8 were key suspects in regulating cholesterol homeostasis in atherosclerotic CVD (ASCVD). This
was supported by the clinical observations of severe, and
sometimes fatal, atherosclerosis in humans with sitosterolemia (though see below). Support for this contention came
from the genome-wide association studies, which showed a
link not only between genetic variations at sitosterolemia
locus (previously referred to as STSL) and lipid levels, but
also for coronary artery disease (14–16). And not surprisingly, because the ABCG5/ABCG8 heterodimer pumps
cholesterol into bile (17–21), this locus was shown to predispose to gallstone disease (22–28). What is surprising,
and the mechanistic connection remains to be addressed,
was the link between a presumed hypermorphic variant,
D19H, in ABCG8 and gallbladder cancer risk (25, 29). This
locus is one of the strongest known genetic risk factors for
this very rare cancer (though the genetic risk remains small).
One pathway of how this may occur is that this variant leads
to increased gall stone formation, subsequent inflammation, and consequently a predisposition to gallbladder cancer; this explanation remains unsubstantiated. Cancer, by
its nature, requires multiple genetic changes to occur and
how this would be caused or accelerated by the sitosterolemia
locus remains to be explored. It is also not clear whether the
variant alters the kinds of xenosterols that are concentrated
1104
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The many clinical manifestations of sitosterolemia have
been well-documented in a number of reviews (10, 32, 33).
In summary, asymptomatic subjects (typically identified by
cascade screening once a proband has been identified) can
manifest no symptoms or signs to varying levels of affectations. There is no question whether affected individuals
can have severe ASCVD, sometimes with fatal presentations
(34–38), but with increased knowledge and case identification, many affected subjects have now been identified, who
in the untreated state, seem to have very little evidence of
ASCVD. Two new studies have now highlighted this. In five
subjects who were diagnosed after investigation of hyperlipidemia (ages 19–32 years), no clinical evidence of
ASCVD was identified (39). More recently, and provocatively,
cascade screening in the Hutterites (where all of the cases
have the same mutations and share a similar lifestyle), many
subjects were identified with no overt clinical manifestation
of ASCVD or any blood dyscrasia (40). The latter study is
also remarkable, as it may shed light on an old observation
by Salen and his colleagues who reported that hepatic LDLreceptor expression was increased, in contrast to the paradoxical suppression of cholesterol biosynthesis enzymes
(41, 42). We had shown that children with sitosterolemia
can manifest very high levels of cholesterol and had previously been misdiagnosed as having pseudo-homozygous
familial hypercholesterolemia (43, 44), yet it is not clear
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xenosterols leads to dramatic phenotypes, such as macrothrombocytopenia and platelet dysfunction, liver disease,
and cholesterol accumulation with xanthoma formation
and atherosclerosis (10), and in mouse models (but not
humans), infertility, immune dysfunction, and cardiomyopathy have been reported (11–13). This begs the question
whether a lifetime of low level exposure to dietary bioactive
xenosterols, whose levels of entry and retention may be altered by polymorphisms in ABCG5 and ABCG8, may have
biological consequences. This review will aim to highlight
areas that, therefore, need further exploration.

why they have such very high levels of plasma cholesterol,
a manifest defect in hepatic clearance of LDL particles.
Mymin et al. (40) reported a nonsignificant inverse association between age and plasma cholesterol; when subjects
were grouped by pre- or postpuberty, both plasma cholesterol and sitosterol levels were significantly higher in prepubertal compared with postpubertal subjects. In one
subject, in the absence of treatment, these sterol levels also
fell progressively with time, though never normalized
(40). This suggests that hepatic expression of lipoprotein
receptors is dramatically altered by the progressive accumulation of xenosterols, and this process is influenced by
puberty.

Liver disease
Although the first case of liver failure associated with
sitosterolemia (52) was regarded as an outlier or coincidence
(and was only interesting as liver transplantation cured the
sitosterolemia), a second case with a fatal outcome has now
been reported. Bazerbachi et al. (53) reported a case of
idiopathic cirrhosis, denied heart transplant from severe
coronary artery disease, only to discover that the patient
had sitosterolemia with the implication that both organ
failures were caused by his one underlying condition. This
raises the issues of the underlying mechanism for liver dysfunction and failure, and how many idiopathic cirrhosis
cases are undiagnosed sitosterolemia. Mutational reviews
of the two cases do not indicate any uniqueness when compared with others with sitosterolemia, and accumulation
of misfolded proteins in the ER, akin to 1-antitrypsin

Transintestinal cholesterol excretion in humans
Until recently, it was assumed that an elevation of plant
sterols in the blood was diagnostic of sitosterolemia. Even
in cases of liver dysfunction and failure, plant sterols remain low and the only clinical scenario where they are elevated is during administration of total parenteral nutrition,
which contains large amounts of plant sterols (54, 55). This
has now been challenged by a report of a case of primary
biliary cirrhosis (PBC), where plant sterols were dramatically elevated (56). It should be noted that plant sterols are
not normally elevated in PBC, thus this is a unique case.
While the speculation was that the liver sterolin function
was affected by this autoimmune process (56), it should be
noted that ABCG5/ABCG8 should remain functionally active in the intestine, and they are key to transintestinal cholesterol excretion (TICE). Thus, TICE should have resulted
in maintaining lower plant sterol levels [akin to the restoration of intestinal sterolin function by transgenes in the
Abcg8 knockout mice (12), or in liver-only knockouts
(57)], but it did not. In PBC, the secretion of bile into the
biliary tree is dramatically reduced and perhaps in this case
there may have been very little bile secreted; this would
mean that for TICE to be effective, loss of all bile in the
intestine may also impair TICE. Groen and colleagues have
shown that the phospholipid content, rather than bile salts,
was a major regulator of TICE (58), opening the avenue
for therapeutic use of dietary phospholipids in cholestatic
diseases to improve lipids via TICE and ABCG5/ABCG8.
And in passing, it should be noted that TICE should be
TISE, because sterols are excreted and continue to bias interpretation in a cholesterol-centric manner.

REGULATION OF ABCG5/G8
The secretion of cholesterol into bile is coupled to the
secretion of phospholipids and bile acids that forms the
mixed micelle acceptors for cholesterol within the aqueous
lumen of the canaliculus. Mouse models of ABCG5/G8 deficiency suggest that the complex accounts for 70–90% of
biliary cholesterol secretion (17, 20, 21), and in mouse
models with a gain or loss of function, there is an approximate gene dosage effect on biliary sterol excretion (17, 18,
20, 59). Factors that increase or decrease the coupling of
biliary cholesterol secretion to bile acids and phospholipids
are likely to be ABCG5/G8 dependent and reflect changes
in either ABCG5/G8 abundance or activity, although it
Cholesterol and xenosterol trafficking
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Macrothrombocytopenia
Macrothrombocytopenia is another phenotype that has
been observed in humans with sitosterolemia (45–47). Remarkably, this phenotype can be the only manifestation of
sitosterolemia. The first description of this entity, Mediterranean macrothrombocytopenia, was reported in Australia
(48), and we suspect it was a cohort of subjects who had sitosterolemia; all of these subjects have been lost to followup to allow confirmation. However, Rees et al. (45) showed
that not only were plant sterols elevated in their cohort in
Europe, they also confirmed mutations at the sitosterolemia locus as causative, a finding that has been now reported from many other sites around the world. This
platelet phenotype is also observed in the murine models
of sitosterolemia (46, 49, 50). Mutations seen in macrothrombocytopenia are also seen in sitosterolemia without
the platelet phenotype, suggesting that these manifestations may be dependent upon the type of xenosterol exposure. While there is no doubt that xenosterol accumulation
leads to platelet dysfunction (50), biogenesis of the platelet
is also abnormal. The mechanism of how xenosterolemia
affects platelet biogenesis remains to be explored. Additionally, it is assumed that these effects are from sitosterol
accumulation (the most abundant accumulating xenosterol), but more bioactive less abundant xenosterols could
be responsible. Other possibilities are bulk xenosterols
altering raft membrane structures, or as a result of displacing
cholesterol from key active sites (51).

deficiency, seems less likely (53). The Finnish case was heterozygous for mutations in ABCG8 (W361X and E423D)
(52), but the US case was homozygous for premature
stop codon in ABCG5 (R446X) (53). If so, then the hypothesis of toxic xenosterol accumulation is again raised.
And if it is a toxic xenosterol species, it may be hard to
detect as most sterol profiles have, to date, been limited to
reporting sitosterol, campesterol, and stigmasterol. Other
lesser known sterols are rarely reported. Expression of
these mutants in vivo may be required to explore these
possibilities.

should be noted that ABCG5/G8-independent biliary cholesterol secretion has been reported (60, 61).
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Regulation of complex formation and trafficking
ABCG5 and ABCG8 are required to form a functional
sterol transport complex. This marriage is formed as the
complex folds in the ER and is dependent on the presence
of N-linked glycans and the calnexin/calreticulin chaperone system (89). Using a series of chimeras comprised of
the N- and C-terminal domains of ABCG1, ABCG2, ABCG5,
and ABCG8, evidence for a an ER-retrieval signal within
the N-terminal cytosolic domains of ABCG5 and ABCG8
that prevents the monomers from exiting the ER prematurely was identified (90). The heterodimer complex formation has now been supported by a high-resolution crystal
structure (91) that will allow for future structure-function
studies to be conducted (Fig. 2, graciously provided by
Dr. Jyh-Yeung Lee, University of Ottawa). Although the
N-terminal structures of ABCG5 and ABCG8 could not be
established within the crystal structure (91), many of the
nonsynonymous polymorphic changes, as well as the missense mutations can be mapped onto a structure (Fig. 2).
The missense mutations (R419 and R550 in ABCG5 and
L572, G574, L596, R573, L501, and L405 in ABCG8) are
very close to the putative sterol-binding pocket [see also
the putative sterol-binding pocket for a model of ABCG4
(92) based upon the ABCG5/ABCG8 crystal structure]. Interestingly, the polymorphic residues, I523 in ABCG5 and
G575 in ABCG8, would also be close to this site and form
good future candidates to explore their effect on sterolspecificity of binding. In polarized cultured hepatocytes,
recombinant ABCG5/G8 was shown to reside at the canalicular membrane (93). Within the small intestine, endogenous mouse, as well as a human, ABCG8 transgenes were
localized almost exclusively to the apical surface (19). However, biochemical fractionation and immunolocalization
approaches suggest a broader intracellular distribution of
ABCG5 and ABCG8 (94). More recently, a recombinant
fluorescently tagged ABCG5/G8 complex was shown to reside in an intracellular pool that is recruited to the canalicular surface in response to a lithogenic diet (95). In
isolated rat liver canalicular membranes, ABCG5 was shown
to reside in Triton-soluble Lubrol-resistant microdomains
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Transcriptional regulation of ABCG5/G8
Expression of sterolins is restricted to the liver, small intestine, and gallbladder epithelium, but the mechanisms
responsible for this limited tissue distribution have not
been elucidated (3, 62, 63). Within these tissues, ABCG5
and ABCG8 are co-regulated at the transcriptional level,
sharing a common bidirectional promoter of 374 base
pairs that separates their initiation codons (3, 62, 64). Regulatory elements within the intergenic region have been
identified for hepatocyte nuclear factor 4 (NR2A1), liver
receptor homolog-1 (NR5A2), nuclear factor kappa-lightchain-enhancer of activated B cells (NFB), and Forkhead
box protein O1 (64–68). Liver X receptor (LXR) response
elements have been mapped to two conserved regions
roughly 100 kB distal to the intergenic promoter, shown to
bind both LXR (NR1H3) and LXR (NR1H2) and synergistically activate the ABCG5/G8 promoter in combination
with retinoid X receptor  (NR2B1), GATA4, hepatocyte nuclear factor 4, and liver receptor homolog-1 (69).
These findings corroborated earlier data in animal models
demonstrating that ABCG5/G8 mRNAs were responsive to
dietary cholesterol as well as LXR and retinoid X receptor
agonists in a LXR- and LXR-dependent fashion (70).
Farnesoid X receptor (FXR; NR1H4) receptor agonists
have also been shown to regulate ABCG5/G8 mRNAs in
cultured hepatocytes, suggesting a direct mechanism of
action. However, FXR response elements have yet to be
mapped for ABCG5/G8 (70, 71). Thus, while a number
of transcriptional factors are implicated in regulating the
sitosterolemia locus, there remains a paucity of direct evidence of their roles.
In vivo, sterolin mRNAs and proteins can be modulated
by a number of experimental conditions. Disruptions of
bile acid metabolism alter hepatic ABCG5/G8 expression,
presumably due to changes in bile acid signaling through
FXR (72–74). Similarly, intestinal expression of ABCG5/
G8 is modulated by bile acids (75, 76). Tissue-specific deletion of hepatic insulin receptors revealed a role for insulin signaling in the regulation of ABCG5/G8 through
Forkhead box protein O1 (67). Alterations in ABCG5/G8
mRNAs have also been observed in experimental models
of type 1 and type 2 diabetes, as well as in human diabetic
subjects (77–81). Additional factors shown to alter hepatic,
intestinal, or gallbladder ABCG5/G8 expression include
thyroid hormone signaling, dietary calcium, iron depletion,
constitutive androstane receptor agonists, and gallbladder
disease (82–86). However, the molecular mechanisms underlying these effects are unclear and the extent to which
they reflect novel regulatory nodes for ABCG5/G8 or are
secondary to disruptions in established regulators is not
known.
CpG islands have been identified near the transcriptional start sites for ABCG5 and ABCG8 and were hypomethylated in the liver and hypermethylated in kidney and
cerebrum (87). This same study revealed differential histone H3 acetylation between liver and these non-ABCG5/

G8-expressing tissues, suggesting that epigenetic mechanisms may control tissue-specific expression of the
complex. A highly intriguing mechanism by which p53
promotes gene expression is by recognition of a structuralspecific motif called triplex DNA (88). The ABCG5 proximal
promoter contains a predicted T·A·T triplex. Expression of
ABCG5 mRNA increased following transient transfection
of p53 in cultured cells, as well as treatment with p53-stabilizing agents in p53-positive cells, but not in p53-negative
cells (88). However, expression of ABCG8 was not examined, the cultured cells were not of hepatic, intestinal, or
gallbladder epithelial origin, and the extent to which this
mechanism influences ABCG5/G8 expression or sterol
metabolism is not known. Interestingly, the insulin receptor was also identified as a T·A·T triplex-responsive gene.
Whether this is coincidental or mechanistically links alterations in insulin signaling and ABCG5/G8 expression is
unclear.

Fig. 2. Localization of nonsynonymous and missense
amino acid changes on a model of ABCG5 (G5)ABCG8 (G8) heterodimer crystal structure. Although
the structures of the N termini of ABCG5 and ABCG8
could not be determined in the crystals subjected to
X-ray diffraction, many of the known mutations and
polymorphic variants could be mapped (91). This figure was kindly provided by Dr. Jyh-Yeung Lee, University of Ottawa.

Regulation of ABCG5/G8 activity
The mechanism by which ABCG5/G8 promotes (chole)
sterol efflux is not fully understood. It was originally suggested that ABCG5/G8 function as a floppase, promoting
the movement of cholesterol to the exofacial leaflet of the
canalicular membrane based on the observation that there
was less cholesterol in isolated canalicular membranes of
ABCG8-deficient mice (98). In cell-based models, coexpression of ABCG5 and ABCG8 will promote cholesterol
efflux to bile-acid micelles, but not other traditional acceptors, such as ApoAI, HDL, or cyclodextrins, indicating that
the molecular mechanism by which ABCG5/G8 promotes
sterol efflux at the apical membrane is distinct from other
cholesterol efflux pumps, such as ABCA1 and ABCG1
(99, 100). Using purified native mouse ABCG5/G8, sterol
transport between donor and acceptor liposomes suggests
a 1:1 stoichiometry for ATP hydrolysis and cholesterol
transport, and bile acids could stimulate this ATP hydrolysis (101). Among the tested bile acids, cholate was the most
potent at stimulating ATPase activity, whereas its taurine or
glycine conjugates were approximately 50% less effective.
Using various lipid extracts and defined preparations, the
presence of cholesterol stimulated ATPase activity to varying degrees. Thus, the presence of both bile acids and cholesterol appear to act cooperatively to activate the pump
and promote cholesterol secretion. This is an attractive
model for the coupling of bile acid and cholesterol secretion and supported by the publication of the ABCG5 and
ABCG8 crystal structures that show a sterol-binding pocket,
which may undergo structural changes upon ATP binding to make this more available at the luminal surface
for phospholipid:bile acid acceptors to allow for excretion
(91). What remains to be established is whether this mechanism is constantly active or is regulated by translocation of
these heterodimers from an intracellular location to the
apical surface. The crystal structure should also allow for

exploration of how missense mutations disrupt function, as
well as how the nonsynonymous polymorphic variants seen
in humans may alter function.
Under a number of conditions, cholesterol and bile secretion can be uncoupled, resulting in reduced cholesterol
excretion or the supersaturation of bile (102). The extent
to which these conditions are due to alterations in ABCG5/
G8 activity awaits further investigation.

MOUSE MODELS USED TO ELUCIDATE
THE IMPACT OF STEROLINS IN PHYSIOLOGY
AND DISEASE
The genes encoding ABCG5 and ABCG8 have been disrupted, as well as overexpressed, in mice in order to perform detailed physiological studies of sterolin function.
Mice lacking functional sterolins in both liver and intestine
have been created by standard gene targeting of Abcg5
(21), Abcg8 (20), or both Abcg5 and Abcg8 (17). Recently,
mice were created with liver- and intestine-specific knockouts of Abcg5 and Abcg8 (57). The integration of the human ABCG5 and ABCG8 genes into the genome of mice
resulted in mouse models with increased sterolin function
in both liver and intestine (18) or liver only (103). In addition, adenoviral vectors have been employed in mice to
increase or restore hepatic ABCG5 and ABCG8 function
(19, 104, 105). These various mouse models have been employed to study the impact of ABCG5/G8 on sterol absorption and secretion, sitosterolemia, reverse cholesterol transport
(RCT), TICE, metabolic disease, and atherosclerosis.
Xenosterol exclusion from the body
Like patients with sitosterolemia, mice lacking ABCG5/
G8 function are unable to preferentially excrete xenosterols into bile or the intestinal lumen. When fed a diet that
contains phytosterols, mice with homozygous disruption of
Abcg5, Abcg8, or both Abcg5 and Abcg8 consistently developed sitosterolemia (12, 17, 20, 21, 46, 49, 72, 106). Plasma
and tissue phytosterol levels in mice with intestinal- or liverspecific knockout of Abcg5 and Abcg8 were significantly less
than those of mice with whole-body ABCG5/G8 deficiency
Cholesterol and xenosterol trafficking
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(96). Similar results were obtained using bile acids as
detergents in which ABCG5, ABCB4, and ABCB11 are colocalized, suggesting the complete biliary lipid secretion
apparatus resides within microdomains at the canalicular
surface (97).

Cholesterol absorption
Action of ABCG5/G8 in the enterocytes is believed to
reduce cholesterol absorption. Fractional cholesterol absorption (FCA) decreased and fecal neutral sterol excretion
(FNSE) increased in transgenic mice with both intestine
and liver (INTLIV-Tg) overexpression of human ABCG5/
G8 (18, 108, 109). In contrast, FCA and FNSE were similar
for wild-type controls and transgenic mice with liver-specific
overexpression of human ABCG5/G8 (103). Because both
transgenic lines had increased biliary cholesterol secretion, the difference in FCA and FNSE between the models
could have been due to the human and mouse ABCG5/
G8 pumping greater amounts of biliary and dietary cholesterol out of the enterocytes and back into the intestinal
lumen of the INTLIV-Tg mice. However, when considering that the INTLIV-Tg mice versus the wild-type controls
had 6- to 7-fold more cholesterol in bile, the absolute
amount of cholesterol absorbed by the INTLIV-Tg mice
versus the wild-type controls would have been significantly
greater even with the 50% reduction in FCA. It is also possible that the increased FNSE was due to the bile of the
INTLIV-Tg mice becoming supersaturated with cholesterol, thus reducing luminal cholesterol bioavailability to
the enterocytes.
If overexpression of ABCG5/G8 decreases FCA and increases FNSE, then it would be anticipated that the absence
of ABCG5/G8 would have the opposite effects. FNSE was
reduced, but FCA, when measured using the fecal dual
1108
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isotope or plasma dual isotope methods, was unchanged in
chow-fed Abcg5/, Abcg8/, and Abcg5/,Abcg8/
mice (17, 21, 72, 110, 111). Cholesterol absorption, as assessed by the movement of luminal-infused cholesterol
into lymph, was found to be decreased in two studies using
Abcg5/,Abcg8/ mice and increased in another study
using Abcg8/ mice (112–114). Compared with wild-type
controls, mice with intestinal-specific ABCG5/G8 deficiency had no changes in FCA or FNSE (57). These studies
indicate that the absence of intestinal ABCG5/G8 does not
lead to increased cholesterol absorption and, consequently,
the reduced FNSE observed in whole-body ABCG5/G8-deficient mice could be driven by dramatically decreased biliary cholesterol secretion. Because most of the above studies
were conducted in mice fed a chow diet (low in fat and
cholesterol, but high in phytosterols), it will be important
to determine the impact of liver and/or intestinal ABCG5/
G8 deficiency on cholesterol absorption in mice consuming a Western-type diet (WTD) with a higher fat and cholesterol content. It will also be essential to assess whether
cholesterol absorption in these models is affected by the
inclusion in the diet of animal- or plant-derived fats that
contain cholesterol and phytosterols, respectively.
Biliary cholesterol secretion
ABCG5/G8 are critical to the secretion of cholesterol
into the bile. Abcg5/, Abcg8/, whole-body, and liverspecific Abcg5/,Abcg8/ mice fed a chow diet displayed
a 70–90% reduction in biliary cholesterol concentration or
secretion (17, 20, 21, 57). In contrast, transgenic overexpression of human ABCG5/G8 in liver and intestine increased biliary cholesterol concentrations by 5-fold and
>7-fold in chow-fed male and female mice, respectively
(18). Biliary cholesterol concentration and secretion by hepatic overexpression of human ABCG5/G8 was unchanged
on a chow diet, but was increased 1.5- to 2-fold on a highcholesterol diet (103). In the absence of the biliary phospholipid transporter, Abcb4, biliary cholesterol concentration
in mice was very low and was not increased by the hepatic
expression of a human ABCG5/G8 transgene, indicating
that biliary phospholipid secretion is required for ABCG5/
G8-mediated cholesterol secretion (108). In addition, studies in which wild-type or Abcg8/ mice were infused with
hydrophilic and hydrophobic bile salts indicated that
ABCG5/G8 drives biliary cholesterol secretion by flopping
cholesterol from the inner to outer leaflet of the canalicular membrane (98). When fed a lithogenic diet, Abcg5/
and Abcg5/,Abcg8/ mice, compared with control
C57BL/6J mice, had decreased incidence of gallstone development (115).
Macrophage RCT
Macrophage RCT (mRCT) is an anti-atherogenic pathway through which excess cholesterol is effluxed from
plaque macrophages, transported on lipoproteins to the
liver, secreted into bile, and excreted from the body. The
primary method used to assess mRCT quantifies the movement of 3H-cholesterol from intraperitoneally injected
macrophage foam cells to feces over 48 h (116). C57BL/6J
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(57). The rescue of intestinal ABCG5/G8 function in
/
mice also significantly reduced, but did not norAbcg8
malize, plasma phytosterol concentrations (12). It can be
concluded that intestinal ABCG5/G8 excretes the majority
of xenosterols back into the lumen, acting as a first-pass
gate. Hepatic ABCG5/G8 then pumps into the bile those
xenosterols that had evaded the intestinal checkpoint.
In the absence of ABCG5/G8 function, xenosterols can
accumulate at high levels in mice causing several pathological conditions. Infertility was observed in male and female
Abcg5/ and Abcg8/ mice consuming a phytosterolrich chow diet, but when phytosterol accumulation in the
body was blocked with a meat-based (xenosterol free) diet,
or the sterol absorption inhibitor, ezetimibe, fertility was
restored (11, 12, 107). Several studies have shown that
mice lacking functional ABCG5/G8 developed macrothrombocytopenia, a disorder characterized by significantly reduced platelet levels and increased platelet size.
Abcg5/, Abcg8/, and Abcg5/,Abcg8/ mice also displayed hemolytic anemia, prolonged bleeding times, and
decreased platelet activation and aggregation (11, 49, 50).
The macrothrombocytopenia and abnormal bleeding was
the result of phytosterol accumulation in platelet membranes
resulting in dysfunctional platelets (50). Mice deficient in
ABCG5 and/or ABCG8 also developed cardiomyopathy
characterized by phytosterol accumulation, histiocytic infiltration, multifocal fibrosis, and tissue calcification (11, 13,
49, 50). Interestingly, the development of cardiomyopathy
is dependent both on the presence of high levels of xenosterols, as well as intact B and T cell function (13).

mice with adenoviral-mediated overexpression of murine
ABCG5/G8 (AdABCG5/G8) displayed increased fecal
macrophage-derived 3H-neutral sterol (i.e., cholesterol),
consistent with an increase in biliary cholesterol secretion.
However, because the sum of 3H-neutral sterol and 3H-bile
acid in feces was similar for AdABCG5/G8 and AdNull controls, it was concluded that increased hepatic ABCG5/G8
function alone does not impact macrophage-to-feces RCT.
Studies in sterolin-deficient mice found that, in spite of significant reductions in biliary cholesterol secretion, mice
lacking ABCG5/G8 function had no deficits in mRCT
(105, 117, 118). However, treatment with LXR agonist increased 3H-neutral sterol excretion from wild-type mice,
but not Abcg5/,Abcg8/ mice, leading to the conclusion that stimulation of mRCT by LXR activation requires
ABCG5/G8 (117).

Atherosclerosis
Atherosclerosis development has been assessed in transgenic mice with both intestine and liver (IntLiv-Tg) and liver
only (Liv-Tg) expression of human ABCG5/G8. Compared
with controls lacking only the LDL receptor (Ldlr/),
IntLiv-Tg;Ldlr/ mice fed a WTD for 6 months had significantly less aortic atherosclerosis (109). The combination of increased biliary cholesterol secretion and decreased
cholesterol absorption in the IntLiv-Tg;Ldlr/ mice resulted in a significant reduction in the plasma cholesterol. In contrast, the Liv-Tg on either the LDLR or ApoE
knockout background did not have reduced atherosclerosis development (103). Liv-Tg;ApoE/ mice fed chow and
Liv-Tg;Ldlr/ mice fed WTD had significantly increased
biliary cholesterol secretion, but compared with controls,

Metabolic disease
ABCG5/G8 function also appears to limit the development of metabolic disease. Sterolin-deficient mice fed a
phytosterol-rich chow diet developed hypertriglyceridemia
due to increases in intestinal triglyceride (TG) absorption
and hepatic TG secretion and reductions in TG-rich lipoprotein clearance and lipoprotein lipase activity (123).
When fed a phytosterol-free high-fat diet, these mice had
increased hepatic TG and cholesterol accumulation leading to liver inflammation, loss of glycemic control, and insulin resistance (124). Obese db/db mice have reduced
hepatic ABCG5/G8 protein and decreased biliary cholesterol (80). Adenoviral-mediated overexpression of ABCG5/
G8 in db/db mice increased biliary cholesterol secretion
and restored hepatic insulin sensitivity resulting in reduced fasting glucose and TGs and improved glucose tolerance (104). However, the relationship between biliary
and intestinal sterol transport and the underlying mechanisms that contribute to metabolic disturbances remain
unclear.

CONCLUSIONS
The human diet is very varied and exposes us to more
than 60 different xenosterols, from shellfish, mushrooms,
yeasts, seaweeds, plants, etc., and we need to have robust
mechanisms to prevent toxic xenosterols from accumulation. The sitosterolemia locus is an evolutionarily conserved locus that has allowed organisms with a liver and
biliary system to perform this function, from fish to man
Cholesterol and xenosterol trafficking
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TICE
TICE is the elimination of plasma cholesterol into the
intestinal lumen by enterocytes. Several studies have indicated that intestinal ABCG5/G8 play an important role in
TICE. Cholesterol fluxes, measured with tracer techniques,
showed that the contribution of TICE to fractional neutral
sterol excretion (FNSE) was 25% in Abcg5+/+ mice, but
15% in Abcg5/ mice (110). Blocking cholesterol absorption with ezetimibe in wild-type mice elevated FNSE by 3.8fold and TICE was responsible for 74% of this increase
(111). Treatment of wild-type mice with the FXR agonist,
PX20606, stimulated FNSE and TICE to a level similar to
that observed with ezetimibe (119). In the absence of ABCG8,
ezetimibe or PX20606 treatment blunted the increase in
FNSE and TICE (111, 119). To gauge the importance of
intestinal ABCG5/G8 in RCT, mice with intestinal-specific
deficiency of ABCG5/G8 were injected with 3H-cholesterol
and the levels of 3H-cholesterol in bile and feces were measured. In spite of similar biliary cholesterol and FCA, the
intestinal-specific ABCG5/G8 knockouts compared with
wild-type control mice had decreased fecal 3H-cholesterol
excretion, likely due to a reduction in TICE (57). In contrast to the above studies, no difference in TICE was observed when measured in wild-type or sterolin mice by
intestinal perfusion (120). The overall results indicate that
ABCG5/G8 play a major role in TICE.

no changes in cholesterol absorption or plasma cholesterol
concentrations were noted. It was concluded that atherosclerosis was unaltered in IntLiv-Tg mice because the increased biliary cholesterol was being absorbed back into
the body. When fed a WTD plus the cholesterol absorption
inhibitor, ezetimibe, Liv-Tg;Ldlr/ compared to Ldlr/
mice displayed significant reductions in total plasma cholesterol and atherosclerosis development (121).
To assess the impact of ABCG5/G8 deficiency and consequently increased phytosterol levels on atherosclerosis
development, whole-body ABCG5/G8-deficient mice expressing or lacking LDL receptor were studied (109). Feeding either a chow diet or WTD for 7 months caused a
significant increase in plasma phytosterol concentration in
/
/
and Abcg5/,Abcg8/;Ldlr/ mice
Abcg5 ,Abcg8
compared with wild-type controls. Regardless of the genotype, atherosclerosis did not develop in mice fed chow. Con/
/
/
sumption of the WTD by the Abcg5 ,Abcg8 ;Ldlr
+/+
+/+
/
mice resulted in similar inand Abcg5 ,Abcg8 ;Ldlr
creases in total plasma sterols and atherosclerosis formation.
Based upon these results, it was concluded that there was no
association between phytosterol levels and atherosclerosis
development in mice. The lack of difference in atheroscle/
/
/
rosis formation between the Abcg5 ,Abcg8 ;Ldlr
+/+
+/+
/
could have been the result
and Abcg5 ,Abcg8 ;Ldlr
of LXR activation by phytosterols offsetting the decreased
biliary cholesterol secretion (122).

The authors are grateful to Dr. Jyh-Yeuan (Eric) Lee for his
generosity in sharing the mapping of the missense mutations
and the non-synonymous polymorphic changes in ABCG5 and
ABCG8 (Fig. 1).
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